Researcher

Brian Kennedy

Last updated Sun May 17 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

Background

Brian Kennedy is Distinguished Professor at the National University of Singapore (NUS) and was president and CEO of the Buck Institute for Research on Aging from 2010 to 2016.

Lines of work

mTOR biology and rapamycin — mechanistic and translational studies.
Alpha-ketoglutarate (AKG) — identified as a metabolite that extends mouse lifespan and improves healthspan; commercial supplement (Rejuvant) trials in humans.
Combination interventions — rather than single drugs.
Asia-focused longevity — aging in Asian populations, Singapore as a geroscience hub.

Influence

Kennedy is one of the central translational voices for moving aging interventions from rodent models into well-designed human trials, and for combination thinking (multiple modest-effect interventions rather than a single “magic bullet”).

Related entries

Rapamycin, mTOR, PEARL trial.

References

Kennedy, B. K. & Lamming, D. W. The mechanistic target of rapamycin: the grand conducTOR of metabolism and aging. Cell Metab. 23, 990–1003 (2016).